(Q51097389)

English

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia

scientific article published in June 1998

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles M. Beasley

3

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

author name string

G D Tollefson

1

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

T M Sanger

2

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

P V Tran

4

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

language of work or name

0 references

publication date

1 June 1998

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

43

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

11

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

803-810

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis.

2 references

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radioreceptor binding profile of the atypical antipsychotic olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Schizophrenics kill themselves too: a review of risk factors for suicide

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Schizophrenia as dopamine-deficiency disease

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Measurement of mood and affect in schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The Causality of Depression in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The significance of depression in the prediction of relapse in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

'Revealed' Depression and Drug Treatment for Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The clinical course of depressive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The Mechanism of Action of Novel Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depressive symptoms in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Negative and positive symptoms in schizophrenia and depression: a followup

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

'Akinetic Depression' in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-3223(98)00093-6

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

release_lzsmuv2y2rabdh4sfcvgnehzlu

1 reference

https://api.fatcat.wiki/v0/release/lzsmuv2y2rabdh4sfcvgnehzlu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 March 2018

http://europepmc.org/abstract/MED/9611669

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51097389&oldid=2267796254"